About Translocating chain-associated membrane protein 1-like 1
Translocating chain-associated membrane protein 1-like 1 (TRAM1L1) is a protein
from Homo sapiens identified by UniProt accession
Q8N609, 369 residues long.
MolForge cross-references it against 0 known binders and
20 disease associations.
Target properties
| Protein name | Translocating chain-associated membrane protein 1-like 1 |
| UniProt accession | Q8N609 |
| Gene | TRAM1L1 |
| Organism | Homo sapiens |
| Length | 369 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (20)
Diseases linked to this target (Open Targets).
- Erythema nodosum · score 0.17
- chronotype measurement · score 0.15
- lifestyle measurement · score 0.15
- response to polyunsaturated fatty acid supplementation · score 0.13
- delta-5 desaturase measurement · score 0.13
- drug use measurement · score 0.08
- alcohol consumption measurement · score 0.05
- wellbeing measurement · score 0.05
- bipolar disorder · score 0.05
- Ataxia-telangiectasia · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8N609-F1 | alphafold | PREDICTED | 80.14 | — |
Amino-acid sequence (369 residues)
MGLRKKSTKN PPVLSQEFIL QNHADIVSCV GMFFLLGLVF EGTAEASIVF LTLQHSVAVP AAEEQATGSK SLYYYGVKDL ATVFFYMLVA IIIHATIQEY VLDKINKRMQ FTKAKQNKFN ESGQFSVFYF FSCIWGTFIL ISENCLSDPT LIWKARPHSM MTFQMKFFYI SQLAYWFHAF PELYFQKTKK QDIPRQLVYI GLHLFHITGA YLLYLNHLGL LLLVLHYFVE LLSHMCGLFY FSDEKYQKGI SLWAIVFILG RLVTLIVSVL TVGFHLAGSQ NRNPDALTGN VNVLAAKIAV LSSSCTIQAY VTWNLITLWL QRWVEDSNIQ ASCMKKKRSR SSKKRTENGV GVETSNRVDC PPKRKEKSS
Explore Translocating chain-associated membrane protein 1-like 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets